ArticleThe journal of headache and pain2020
Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database.
Article in The journal of headache and pain, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Efficacy and Safety of Oral Chinese Herbal Medicine for Migraine: A Systematic Review and Meta-Analyses Using Robust Variance Estimation Model.Frontiers in neurology · 2022Pooled it
- Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study.The journal of headache and pain · 2026Trial
- Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial.The journal of headache and pain · 2024Trial
- A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.The journal of headache and pain · 2022Trial
- Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study.The journal of headache and pain · 2022Trial
- Current landscape of migraine care with expert consensus from East Asia.The journal of headache and pain · 2026Review
- Trends and age-period-cohort analysis of migraine incidence in China from 1990 to 2021.PloS one · 2026Article
- A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Intranasal Dose of Zavegepant in Healthy Chinese Adults.Clinical pharmacology in drug development · 2026Article
- Cost-utility analysis of erenumab preventive treatment for chronic migraine in China.Frontiers in public health · 2026Article
- Use of Drugs With Actionable Pharmacogenetic Biomarkers and Possible Prescribing Changes Among Older People.Journal of the American Geriatrics Society · 2025Article
- Primary healthcare quality of migraine in China: a study using unannounced standardized patients.The Lancet regional health. Western Pacific · 2025Article
- A summary of the current circumstances of migraineurs in China: a review of the GBD2019 database.Frontiers in human neuroscience · 2025Review
- Potentially Inappropriate Medication and Associated Factors Among Older Patients with HIV/AIDS: A Multicenter Cross-Sectional Study.Clinical interventions in aging · 2025Article
- Fu's Subcutaneous Needling treatment for migraine without aura: a randomized controlled trial protocol.Frontiers in neurology · 2025Article
- Cost-effectiveness analysis of bevacizumab for cerebral radiation necrosis treatment based on real-world utility value in China.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Prevalence and disease burden of chronic cough in nine cities of China: an observational study.BMC pulmonary medicine · 2024Observational
- Trends and prescribing patterns of antimigraine medicines in nine major cities in China from 2018 to 2022: a retrospective prescription analysis.The journal of headache and pain · 2024Article
- Healthcare utilisation and economic burden of migraines among bank employees in China: a probabilistic modelling study.The journal of headache and pain · 2024Article
- Cost-effectiveness analysis of rimegepant for on-demand acute treatment of migraine in China.Frontiers in neurology · 2024Article
- Real-world observations and impacts of Chinese herbal medicine for migraine: results of a registry-based cohort study.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAdult migraine remains underdiagnosed and undertreated, despite significant negative effects on physical and emotional functioning. Information on prescribing patterns and treatment costs of migraine in China is limited.
methodsThis retrospective analysis of the China Health Insurance Research Association (CHIRA) medical insurance claims database in 2016 to 2017 evaluated treatment patterns, direct medical costs, and healthcare resource utilization among adults with migraine in mainland China.
resultsOf 108,375 patients with headache-related outpatient visits, 10,652 were adults with migraine (mean age 51.4 years, 55.4% female). Common comorbidities were major depressive disorder (4.1%), insomnia (3.8%), and anxiety (2.3%). Migraine patients were prescribed acute medication (26.4%), preventive medication (15.0%), and Chinese patent and herbal medicines (24.5% and 11.7%, respectively). Of patients prescribed acute medication, 68.8% received non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs), 7.1% received opioids, while only 3.3% received triptans. Mean annual outpatient costs per patient were 46.5 United States dollars (USD), with mean (standard deviation) 1.8 (2.0) outpatient visits per year. Medication costs for traditional Chinese medicine (22.4 USD per patient) were higher than for Western medicine (13.5 USD).
conclusionAmong migraine patients in China, NSAIDs were commonly prescribed as acute medication, while utilization of migraine-specific triptans and preventive medications was low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.